Kenda R, Musumeci R, Uslenghi C
Lymphology. 1975 Sep;8(3):84-90.
From 1961 to 1969 426 patients (208 with Hodgkin's disease and 218 with non-Hodgkin's lymphoma) underwent endolympatic radiotherapy with Lipiodol 131I at the National Cancer Institute of Milano. For this study, only those patients with stage I, II, or III disease (with or without systemic symptoms), who were not previously treated, and who had a complete follow-up were reviewed. It appears that while in the cases where there is lymphographic evidence of involved lymph nodes, endolymphatic radiotherapy is not of value, in the cases with apparently negative lymphography, endolymphatic radiotherapy can reduce the incidence of relapse in the inguino-retroperitoneal nodes to a statistically significant degree.
1961年至1969年期间，426例患者（208例患有霍奇金病，218例患有非霍奇金淋巴瘤）在米兰国家癌症研究所接受了碘油131I内淋巴放疗。在本研究中，仅对那些处于I期、II期或III期疾病（有或无全身症状）、未曾接受过治疗且有完整随访资料的患者进行了回顾。似乎在有淋巴管造影证据显示淋巴结受累的病例中，内淋巴放疗没有价值，而在淋巴管造影明显阴性的病例中，内淋巴放疗可将腹股沟 - 腹膜后淋巴结复发率降低至具有统计学意义的程度。
